Streetbeat News

Analyst Ratings

TNDM

Barclays has maintained an Overweight rating on Tandem Diabetes Care but lowered its price target from $71 to $62. This has led to a decrease in Tandem's share price.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:33 pm

VNT

Barclays analyst Julian Mitchell maintains an Overweight rating on Vontier (NYSE:VNT) and raises the price target from $35 to $40.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:33 pm

VC

Barclays analyst Raimo Lenschow maintains an Underweight rating on Visteon (NASDAQ:VC) and raises the price target from $130 to $135.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:31 pm

LAUR

Laureate Education's stock has been upgraded from Equal-Weight to Overweight by Morgan Stanley, which also raised its price target from $15 to $17.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:31 pm

TILE

Truist Securities analyst Keith Hughes maintains a 'Hold' rating on Interface (NASDAQ:TILE) and raises the price target from $8 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 2:30 pm

VLO

Barclays analyst Theresa Chen maintains an Overweight rating on Valero Energy (NYSE:VLO) and raises the price target from $139 to $142.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:30 pm

GMED

Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Globus Medical (NYSE:GMED) and lowers the price target from $68 to $65.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 2:29 pm

EOG

Truist Securities analyst Neal Dingmann has maintained a 'Buy' rating on EOG Resources (NYSE:EOG) and raised the price target from $150 to $160.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 2:28 pm

CRD

Truist Securities analyst Mark Hughes has maintained a 'Buy' rating on Crawford & Company Common Stock (NYSE:CRD) and raised the price target from $10 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 2:28 pm

TNDM

Barclays analyst Matt Miksic has maintained an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowered the price target from $71 to $62.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 2:27 pm